NCT04091490View on ClinicalTrials.gov

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Nivolumab

Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab

Trial Locations (1)

105203

The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow

All Listed Sponsors
lead

State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

OTHER

NCT04091490 - Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) | Biotech Hunter | Biotech Hunter